Iovance Biotherapeutics, Inc. announces the FDA acceptance of its BLA submission

WEST WARWICK, Rhode Island
May, 2023

Another step toward commercial approval, Iovance Biotherapeutics, Inc. announced yesterday that with the FDA acceptance of its BLA submission for its lifileucel cell therapy and its Priority Review status, its PDUFA date is November 25 this year. Furthermore, the FDA is not currently planning to hold an advisory committee meeting to discuss this application and, after a preliminary review, has not at this time identified any potential review issues. So close now!

About Blood Centers of America
 Blood Centers of America (BCA) is a member-owned organization comprised of over 50 independent blood centers throughout the North America, representing nearly 40% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, other BCA member services include patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries.